Skip to content

Randomized, Split-Side, Double Blinded, Placebo-Controlled study, the Efficacy of Intralesional Injection of Botulinum Toxin Type A versus 0.9% NaCl for the Treatment of Scalp Psoriasis

Randomized, Split-Side, Double Blinded, Placebo-Controlled study, the Efficacy of Intralesional Injection of Botulinum Toxin Type A versus 0.9% NaCl for the Treatment of Scalp Psoriasis

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
TCTR
Registry ID
TCTR20181214001
Enrollment
18
Registered
2018-12-14
Start date
2018-06-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

&#45

Interventions

Intrasional 0.9% NaCl injection in 16 cm2 of scalp psoriasis lesion in another side of head,Intrasional Botulinum toxin type A injection in 16 cm2 of scalp psoriasis lesion in one side of head
Intralesional 0.9% NaCl Injection,Intralesional Botulinum toxin A Injection

Sponsors

The Royal College Physicians of Thailand
Lead Sponsor
Dermatological Society of Thailand
Collaborator

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: - Age 18-60 - Diagnosed psoriasis by clinical or histopathology with scalp involvement - lesion of scalp psoriasis at least 16 cm2 area both side of scalp - all participants are informed consent

Exclusion criteria

Exclusion criteria: - There are other scalp conditions - Pregnancy or lactation - Botulinum toxin A, human albumin of lactose allergy - There is medical condition eg. myasthenia gravis, amyotrophic lateral sclerosis - Tendency to bleeding - Currently use aminoglycosides

Design outcomes

Primary

MeasureTime frame
mean difference change in modified Psoriasis Severity Index week 0,2,4,8,12 scoring

Secondary

MeasureTime frame
Sebum production week 0,2,4,8,12 Sebumeter,Sweat production week 0,2,4,8,12 Iodine starch test, hyperhidrosis Disease Severity Scale,Quality of life week 0,2,4,8,12 Questionnaire (Dermatology life quality index),itching symptom week 0,2,4,8,12 Visual analogue scale

Countries

Thailand

Contacts

Public ContactKatkanit Thammakumpee

Government

tkatkanit@gmail.com0993159195

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026